GU Cancer ESMO 2023 Highlights

Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.

Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.

Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Following their program on data updates in GU cancer from ESMO 2023, Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, share key takeaways from SunRISe-1, EV-302, and PSMAfore.